3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
4
Lung Neoplasms
2
Recurrence
1
Non-Small Cell Lung Cancer ALK-positive
1
Neoplasm Metastasis
1
Meningeal Carcinomatosis
1
Glioma
1
Glioblastoma
1
Diffuse Intrinsic Pontine Glioma
1
Brain Neoplasms
1
Astrocytoma
1
Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
1
Advanced Non-Small Cell Lung Cancer
1
ALK Positive Non-small Cell Lung Cancer
1
Interventions
pembrolizumab
17
Cisplatin
15
Magnetic Resonance Spectroscopy
14
Specimen Handling
13
Carboplatin
11
Paclitaxel
9
Platinum
8
1,2-diaminocyclohexaneplatinum II citrate
8
Radiotherapy, Intensity-Modulated
6
Cetuximab
6
durvalumab
5
Radiotherapy
5
Radiation
5
Pemetrexed
5
Biopsy
5
cemiplimab
4
Nivolumab
4
Ipilimumab
4
Fluorouracil
4
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
4
(225)Ac-DOTA-c(RGDyK)
4
poly ICLC
3
osimertinib
3
Taxes
3
Oxaliplatin
3
ipatasertib
2
fludarabine phosphate
2
fludarabine
2
cabozantinib
2
atezolizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma
×
lorlatinib
×
90 days
×
Clear all
No trials found.